CollabRx Forms Editorial Board for Prostate Cancer

CollabRx Forms Editorial Board for Prostate Cancer

E. David Crawford, M.D. Named as Chief Editor

SAN FRANCISCO, Feb. 19, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX)
today announced the formation of an editorial board for prostate cancer to be
led by E. David Crawford, M.D. who will serve as Chief Editor. Dr. Crawford is
the distinguished Professor of Surgery, Urology, and Radiation Oncology, and
head of the Section of Urologic Oncology at the University of Colorado
Anschutz Medical Campus. He is an active clinician, researcher, and teacher
who has been recognized as one of the Best Doctors in America, one of the Best
Cancer Doctors, and one of the Top 20 Urologists in the country by Men's
Health Magazine.Dr. Crawford will lead a distinguished group of physicians
from leading institutions such as Yale University, University of Michigan,
Cleveland Clinic, Dana-Farber Cancer Institute, and others.The complete
editorial board can be found on the company's website
(http://www.collabrx.com/expert-affiliations/cancer-specific-editorial-boards/prostate-cancer/).

The board's initial activities will focus on the creation of a Therapy Finder™
app for advanced prostate cancer.To develop this app, editorial board members
will work with CollabRx scientists to identify and synthesize information
relevant for prostate cancer treatment planning including clinical guidelines,
drugs and other therapies, clinical trials, and diagnostics.The new app will
extend the CollabRx Therapy Finder™ product line, which currently covers
colorectal cancer, melanoma, and lung cancer.Knowledge in Therapy Finder™
apps is kept dynamically up-to-date by internal CollabRx scientists using the
company's proprietary semantic integration platform, a technology developed by
CollabRx to enable the efficient and semi-automated gathering, annotation, and
curation of the world's knowledge on molecular medicine for oncology.

"The formation of an editorial board for prostate cancer supports the
company's strategy to provide essential knowledge to inform treatment
planning, at the point of care, for all commonly lethal cancer types," said
Thomas Mika, President & CEO of CollabRx. "We are honored that Dr. Crawford
and his board members have joined our large and growing expert advisory
network and will work with us to develop tools and services to assist
physicians in treating the estimated 240,000 men who are diagnosed with
prostate cancer each year in the U.S."

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform health care decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com and http://www.cancer.org.

The CollabRx, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16990

CONTACT: Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350
        
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         robert.ferri@robertferri.com

CollabRx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.